Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy

November 4, 2011 updated by: Sang-Uk Han, Ajou University School of Medicine

Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy for Gastric Cancer Patients : Prospective Randomized Study

The purpose of this trial is to compare the degree of reflux, operative outcomes and quality of life between Roux en Y and Billroth-I reconstructions after distal subtotal gastrectomy for gastric cancer

Study Overview

Status

Unknown

Conditions

Detailed Description

Most common procedure for the resection of gastric cancers located in middle or lower stomach is distal subtotal gastrectomy. However, the optimal reconstruction procedure after that has still not to be established. Although B-I reconstruction is most common method due to the safety and simplicity, the duodenal fluid may reflux into the remnant stomach which may contribute to the mucosal injury to remnant stomach and esophagus. Roux en Y reconstruction may reduce the reflux to remnant stomach due to the length of Roux en Y limb, although it is more complicated procedure.

Therefore, we plan to collect 120 patients to compare the degree of reflux between Roux en Y and Billroth-I reconstructions after distal subtotal gastrectomy for gastric cancer. In addition, we compare the surgical outcome and quality of life between two groups.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Suwon, Korea, Republic of, 422-749
        • Recruiting
        • Ajou University Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sang-Uk Han, M.D., Ph.D.
        • Sub-Investigator:
          • Hoon Hur, M.D.
        • Sub-Investigator:
          • Young Bae Kim, M.D.
        • Sub-Investigator:
          • Jun Young Kim, M.D.
        • Sub-Investigator:
          • Sun Mi Uhm, N.R.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients diagnosed with adenocarcinoma at the endoscopic biopsy
  • Patients who are possible to be performed curative resection in imaging study
  • Patients with tumor which not involved in pylorus and are located in mid or distal portion of the stomach
  • Patients with informed consent
  • Patients with three or less American Society Anesthesiology Score 3

Exclusion Criteria:

  • Patients who are or become pregnant
  • Patients with uncontrolled disease
  • Patient s with synchronous other malignancy
  • Patients participated in other clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Billroth-I
Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
Other Names:
  • Gastroduodenostomy
Experimental: Roux en Y
Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
Other Names:
  • Gastrojejunostomy and jejunojejunostomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reflux of bile content
Time Frame: 6 months after surgery
We estimate the degree of reflux by gastrofiberscopic findings using reflux score suggested by Romaganoli. In addition, histological finding of remnant stomach by endoscopic biopsy is also investigated. Reflux symptom is surveyed by Gastrointestinal Symptom Rating Scale.
6 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life
Time Frame: 6 months after surgery
We investigate the quality of life with EORTC-C30, EORTC-STO22 questionnaire suggested by European Organization for Research and Treatment of Cancer (EORTC).
6 months after surgery
Morbidity
Time Frame: 2 month after surgery
We investigate the occurrence of complication during recovery after surgery.
2 month after surgery
Anastomotic time
Time Frame: Day 1
We estimate anastomosis time
Day 1
Nutritional state
Time Frame: 6 month after surgery
We estimate Albumin, transferrin, lymphocyte, body weight
6 month after surgery
Mortality
Time Frame: 2 month after operation
We investigate the occurrence of operation-related death during recovery after surgery.
2 month after operation
Operation time
Time Frame: Day 1
We estimate total operation time.
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sang-Uk Han, M.D., Ph D., Department of surgery, Ajou University School of Medicine
  • Study Director: Hoon Hur, M.D., Department of surgery, Ajou University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2010

Primary Completion (Anticipated)

May 1, 2012

Study Completion (Anticipated)

May 1, 2012

Study Registration Dates

First Submitted

June 8, 2010

First Submitted That Met QC Criteria

June 10, 2010

First Posted (Estimate)

June 11, 2010

Study Record Updates

Last Update Posted (Estimate)

November 6, 2011

Last Update Submitted That Met QC Criteria

November 4, 2011

Last Verified

November 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • AJIRB-MED-DEO-09-297

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrectomy

Clinical Trials on Billroth-I

3
Subscribe